

**Amendments to the Claims:**

Please cancel claims 2, 5, 7-9 and 11-58.

The remaining claims are 1, 3, 4, 6, 10 and 59-64.

This listing of claims replaces all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Original) A pharmaceutical composition comprising an effective amount of bioactive trans-tetracos-15-enoic acid extracted from a plant *Indigofera tinctoria*, used for the treatment of subjects with hepatic disorders.

2. (Cancelled)

3. (Original) A composition according to claim 1 wherein trans-tetracos-15-enoic acid is used singly or in combination with pharmaceutically acceptable additives.

4. (Original) A composition according to claim 1 wherein the pharmaceutically acceptable additives are selected from the group consisting of carriers, diluents, solvents, filters lubricants, excipients, binder or stabilizers.

5. (Cancelled)

6. (Original) A composition according to claim 1 wherein said composition is used systemically, orally or by any clinically/medically accepted methods.

7. – 9. (Cancelled)

10. (Original) A composition according to claim 1, wherein the subjects is selected from the group consisting of humans and mammals, preferably humans.

11. – 58. (Cancelled)

59. (Previously Presented) A composition according to claim 1 in which said bioactive trans-tetracos-15-enoic acid is extracted by a process comprising extracting the powdered plant parts of a plant from the species *Indigofera tinctoria* with an aliphatic hydrocarbon solvent, obtaining a residue from the extract, purifying the residue by chromatography to yield a bioactive fraction and crystallizing bio-active trans-tetracos-15-enoic acid from the fraction using an alcoholic solvent.

60. (Previously Presented) The composition of claim 59 in which the extraction is performed at a temperature in the range of 60-80°C for about 20-30 hours.

61. (Previously Presented) The composition of claim 59 in which the residue is obtained by triturating the extract with a ketonic solvent.

62. (Previously Presented) The composition of claim 59 in which the chromatography comprises claim 60 in which said process further comprises the use of one or more of: a) a silica gel bed; b) column chromatography by eluting with a mixture of organic solvents of increasing polarity to yield a bioactive fraction; and c) high performance liquid chromatography.

63. (Previously Presented) The composition of claim 59 in which the aliphatic hydrocarbon solvent is petroleum ether.

Applicant : Handa et al.  
Serial No. : 10/073,548  
Filed : February 11, 2002  
Page : 4 of 8

Attorney's Docket No.: 07064-012001 / FP00820-  
NF236/99-VK

64. (Previously Presented) The composition of claim 59 in which the alcoholic solvent is methanol or isopropanol.